| Q42992255 | Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database |
| Q35184579 | Antiretroviral-associated liver injury |
| Q35883375 | Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand |
| Q30387567 | Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women |
| Q35693265 | Challenges in the management of HIV and hepatitis C virus co-infection |
| Q35676509 | Clinical vignette in antiretroviral therapy: jaundice |
| Q35635844 | Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. |
| Q37699731 | Drug-Induced Liver Injury in HIV Patients |
| Q35676417 | Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors |
| Q37139458 | EFV/FTC/TDF-associated hepatotoxicity: a case report and review |
| Q24235724 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
| Q35542957 | Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city |
| Q36008539 | Hepatotoxicity of antiretrovirals: incidence, mechanisms and management |
| Q36094448 | Hyperbilirubinemia in the setting of antiviral therapy |
| Q78601142 | Pharmacoepidemiology and drug safety |
| Q37232075 | Review article: The use of potentially hepatotoxic drugs in patients with liver disease |
| Q36409500 | Treatment of hepatitis C in HIV-coinfected patients |
| Q80426454 | [Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease] |